Neuren Pharmaceuticals (ASX:NEU) has announced the initiation of the first investigational site in the US for its Phase 3 clinical trial of NNZ-2591 in Phelan-McDermid syndrome, after receiving Institutional Review Board approval. …
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 Australian Biotech
Latest Video
New Stories
-
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 25, 2025 - - Australian Biotech -
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech -
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech -
Argent BioPharma announces results of independent in vivo study
August 25, 2025 - - Australian Biotech -
An outcome that might haunt the system's decision-making, like Banquo's ghost
August 25, 2025 - - Latest News -
Disappointment as committee stalls again on broad listing for cancer immunotherapies
August 25, 2025 - - Latest News -
PBAC delivers recommendations dominated by price cuts and risk shares
August 25, 2025 - - Latest News